Mandate

Vinge advises Oncorena

January 13, 2022

Vinge advises Oncorena Holding AB in connection with an investment of initially SEK 66 million from Linc, HealthCap and Fåhraeus Startup and Growth.

The investment will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer. In the event that the initial part of the clinical study provides positive results, the investors intend to finance the second part of the study with an additional SEK 94 million.

 

The Vinge team includes Christian Lindhé, Martin Svanberg and Sofie Nordgren.

Related

Vinge advises KEYTO Group in connection with the acqusition of Säkra Larm

KEYTO Group continues to broaden its home services offering as Säkra Larm joins the Group, establishing home security as a new business vertical within KEYTO. The addition marks another important step in KEYTO's ambition to become the leading one-stop destination for services connected to the home.
September 24, 2026

Vinge has advised Ingrid Capacity in connection with the formation of a strategic partnership with Mirova for a strategic partnership for a large-scale BESS portfolio in the Nordics

Ingrid Capacity and Mirova, an affiliate of Natixis Investment Managers dedicated to sustainable investment, announce a cross-border partnership of two BESS projects totalling 145 MW/290 MWh in Sweden and Finland. Vinge has advised Ingrid Capacity in connection with the formation of the partnership.
September 24, 2026

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026